Literature DB >> 24631859

Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site.

Hanne M Kinnunen1, Randall J Mrsny2.   

Abstract

Subcutaneous (SC) injection is currently the most common route of self-administering biopharmaceuticals such as proteins and peptides. While pharmaceutical scientists have acquired great skill in identifying formulations for these proteins and peptides with multi-year shelf life stability, the SC injection of these formulations can result in inconsistent or particularly low bioavailability outcomes. We hypothesise that upon injection, the chemical, physical and physiological properties of the subcutaneous tissue may play a crucial role in determining the therapeutic outcomes of SC injected biopharmaceuticals. We contend that physical and chemical stresses placed upon the injected protein or peptide as it transitions from the non-physiological environment of its formulation to the homeostatic conditions of the SC tissue can affect its fate following injection, and that by taking this environment into account when formulating, more precisely controlled release of SC injected biopharmaceuticals could be achieved. In this mini-review we describe how events that occur to an injected protein or peptide during this post-injection transition period could affect the diffusion of bioactive material to blood capillaries and lymphatic vessels. With this in mind, we have reviewed the chemical, physical and physiological attributes of the SC tissue and collated studies on how these properties are known to affect protein stability and diffusional properties. Finally, examples where the understanding of the properties of the SC tissue when formulating for SC injected biopharmaceuticals has improved the predictability of drug delivery via the SC route are discussed, with the need for novel tools for rational and informed formulation development highlighted.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biopharmaceuticals; Formulation; Subcutaneous injection

Mesh:

Substances:

Year:  2014        PMID: 24631859     DOI: 10.1016/j.jconrel.2014.03.011

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  24 in total

1.  Glatiramer acetate persists at the injection site and draining lymph nodes via electrostatically-induced aggregation.

Authors:  Jimmy Y Song; Nicholas R Larson; Sharadvi Thati; Irma Torres-Vazquez; Noraida Martinez-Rivera; Natalia J Subelzu; Martin A Leon; Eduardo Rosa-Molinar; Christian Schöneich; M Laird Forrest; C Russell Middaugh; Cory J Berkland
Journal:  J Control Release       Date:  2018-11-07       Impact factor: 9.776

2.  Docetaxel Accumulates in Lymphatic Circulation Following Subcutaneous Delivery Compared to Intravenous Delivery in Rats.

Authors:  Deanna R Worley; Ryan J Hansen; Luke A Wittenburg; Laura S Chubb; Daniel L Gustafson
Journal:  Anticancer Res       Date:  2016-10       Impact factor: 2.480

3.  Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.

Authors:  Shihao Hu; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-06-04       Impact factor: 2.745

Review 4.  In Vivo Stability of Therapeutic Proteins.

Authors:  Joachim Schuster; Atanas Koulov; Hanns-Christian Mahler; Pascal Detampel; Joerg Huwyler; Satish Singh; Roman Mathaes
Journal:  Pharm Res       Date:  2020-01-03       Impact factor: 4.200

5.  Winner of the society for biomaterials young investigator award for the annual meeting of the society for biomaterials, April 11-14, 2018, Atlanta, GA: S-nitrosated poly(propylene sulfide) nanoparticles for enhanced nitric oxide delivery to lymphatic tissues.

Authors:  Alex Schudel; Lauren F Sestito; Susan N Thomas
Journal:  J Biomed Mater Res A       Date:  2018-03-05       Impact factor: 4.396

Review 6.  Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.

Authors:  Michael R Turner; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2018-01-11       Impact factor: 3.534

Review 7.  Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins.

Authors:  Xing Jing; Yan Hou; William Hallett; Chandrahas G Sahajwalla; Ping Ji
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 8.  Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.

Authors:  Andrew Owen; Steve Rannard
Journal:  Adv Drug Deliv Rev       Date:  2016-02-23       Impact factor: 15.470

9.  Multiphysics Modeling and Simulation of Subcutaneous Injection and Absorption of Biotherapeutics: Sensitivity Analysis.

Authors:  Peng Hou; Fudan Zheng; Clairissa D Corpstein; Lei Xing; Tonglei Li
Journal:  Pharm Res       Date:  2021-06-02       Impact factor: 4.200

10.  Clinical Evaluation of an Investigational 5 mL Wearable Injector in Healthy Human Subjects.

Authors:  Wendy D Woodley; Wen Yue; Didier R Morel; Audrey Lainesse; Ronald J Pettis; Natasha G Bolick
Journal:  Clin Transl Sci       Date:  2021-03-25       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.